Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.32 |
| ▸ | REN | P00797 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caprolactam SCHEMBL4708253 | 0.84 | DPP4 (0.51) | DPP4DPP7KCNH2DPP8 | |
| SCHEMBL8255180 | 0.71 | DPP4 (0.63) | DPP4DPP7KCNH2DPP8 | |
| Caprolactam SCHEMBL1846964 | 0.70 | DPP4 (0.50) | DPP4DPP7KCNH2DPP8 | |
| SCHEMBL5132612 | 0.70 | DPP4 (0.41) | DPP4DPP7KCNH2DPP8 | |
| SCHEMBL5041276 | 0.70 | DPP4 (0.66) | DPP4DPP7KCNH2DPP8 | |
| SCHEMBL29196909 | 0.69 | DPP4 (0.55) | DPP4DPP7KCNH2DPP8 | |
| SCHEMBL30786697 | 0.69 | DPP4 (0.55) | DPP4DPP7KCNH2DPP8 | |
| SCHEMBL19500634 | 0.68 | DPP4 (0.43) | DPP4KCNH2 | |
| SCHEMBL344600 | 0.68 | DPP4 (0.43) | DPP4 | |
| SCHEMBL344599 | 0.68 | DPP4 (0.43) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651623-B1 | HEXAHYDRODIAZEPINONES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-12-17 | — | — | EP | disclosed |
| US-7259160-B2 | Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20060211682-A1 | Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211682-A1 | Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885KCNH2 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.